GlassScriptPhysician profile
Mukesh B Patel
NPI 1902835325
$4,319.16
in general payments reported to CMS, 2019-2025
29 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $378 · 2021: $433 · 2022: $770 · 2023: $378 · 2024: $911 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064 · Gift: $20.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,063.64 |
| Gift | $20.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,784.43 | 2019-2025 | |
| Braintree Laboratories, INC. | $483.56 | 2019-2023 | Suflave |
| Regeneron Healthcare Solutions, INC. | $273.49 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.26 | 2019-2023 | Trulance |
| Janssen Biotech, INC. | $197.96 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $158.36 | 2024 | |
| Ardelyx, INC. | $155.37 | 2024-2025 | Ibsrela |
| Axonics, INC. | $144.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.43 | 2019-2023 | Gattex, Entyvio |
| Nestle Healthcare Nutrition INC. | $104.38 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $93.24 | 2024 | |
| Qol Medical, LLC | $81.29 | 2022-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $71.19 | 2019-2023 | Dificid |
| Celgene Corporation | $55.35 | 2023-2024 | Zeposia |
| Boston Scientific Corporation | $51.59 | 2022-2024 | Cre Pro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $47.44 | 2023 | Aemcolo, Movantik, Talicia |
| Celltrion USA INC. | $44.65 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $40.35 | 2024 | Voquezna |
| Medtronic, INC. | $33.41 | 2023-2024 | Gi Genius |
| Gilead Sciences, INC. | $27.16 | 2019-2021 | |
| Madrigal Pharmaceuticals | $20.85 | 2025 | Rezdiffra |
| Novo Nordisk INC | $18.53 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $18.05 | 2022 | |
| W. L. Gore & Associates, INC. | $17.43 | 2020 | |
| Shionogi INC | $17.08 | 2019 | |
| Blueprint Medicines Corporation | $16.98 | 2024 | Ayvakit |
| Pfizer INC. | $16.19 | 2020 | |
| Intercept Pharmaceuticals, INC. | $14.40 | 2024 | |
| Concordia Pharmaceuticals INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.